MedTrace Logo

A Study in Healthy People to Test Whether Iclepertin Has an Effect on Cardiac Safety

NCT06070597 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-07-09

No results posted yet for this study

Summary

This study aims to evaluate the effects of iclepertin in the range of therapeutic to supra-therapeutic exposures on the (QT/QTc): Electrocardiogram (ECG) time interval from the start of the QRS complex (ECG time interval) to the end of the T wave / QT interval corrected for heart rate, e.g. using the method of Fridericia or Bazett interval and other ECG parameters.

Conditions

  • Healthy

Interventions

DRUG

Iclepertin

Iclepertin

DRUG

Iclepertin Placebo

Placebo to Iclepertin

DRUG

Moxifloxacin

Moxifloxacin

DRUG

Moxifloxacin Placebo

Placebo Moxifloxacin

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-25
Primary Completion
2024-06-05
Completion
2024-06-05

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06070597 on ClinicalTrials.gov